- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02459769
Exercise Intervention for LGBT Cancer Survivors
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender (LGBT) Cancer Survivors and Caregivers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed randomized controlled trial aims to recruit 70 lesbian, gay, bisexual, and transgender (LGBT) cancer survivors who have completed treatment (surgery, radiation, or chemotherapy) within the past 24 months, so as to have a final, evaluable sample of 60 LGBT survivors after attrition. The proposed RCT will also recruit caregivers (broadly defined) of the above cancer survivors. Each recruited cancer survivor will be asked to name a person who they feel provided care (emotional, informational, tangible, etc.) during their cancer experience, with no further strictures placed on this relationship in terms of type or duration. The caregiver will be approached to participate in the RCT. Thus the sample will consist of 70 LGBT survivors (60 evaluable) and their caregivers (140 individuals total/120 evaluable). Recruitment and primary analyses will specifically target the LGBT cancer survivor.
All data will be gathered from participants 21 years of age or older. Participants are cancer survivors who have completed treatments or caregivers of cancer survivors; both survivors and caregivers are able to read and understand English.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- (Survivors): To be included in the study, cancer survivors must:
- Have had a diagnosis of cancer (any cancer type excluding squamous and basal cell [skin cancers]) and have completed primary surgery, chemotherapy, and/or radiation (those on continued adjuvant treatment are still eligible),
- Identify as lesbian, gay, bisexual, or transgender, or have a same-sex romantic partner,
- Have a caregiver willing to participate in the study (defined as anyone who provided emotional support or tangible assistance during the survivors' cancer experience),
- Be able to read English,
- Be 21 years of age or older, and
- Give written informed consent.
- (Caregivers): Caregivers must:
- Be nominated by a cancer survivor,
- Be able to read English,
- Be 21 years of age or older,
- Give written informed consent.
Exclusion Criteria:
- Have physical limitations (e.g., cardiorespiratory, orthopedic) contraindicating participating in a low- to moderate-intensity home-based walking and progressive resistance program and physical function testing, as assessed by their medical oncologist, their primary care physician, and/or the study medical monitor (or any of these three physicians' designees),
- For caregivers, be currently undergoing active treatment for cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Dyadic Exercise Intervention
Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks).
Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
|
a standardized, daily, 6 week, home-based, progressive exercise program
Other Names:
|
|
Other: Individual Exercise Intervention
Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks).
The caregiver is told not to change his/her exercise behavior in any way.
|
a standardized, daily, 6 week, home-based, progressive exercise program
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Reported Psychological Distress
Time Frame: Assessed at 8 weeks
|
Self-reported psychological distress was measured with the Profile of Mood States (POMS) total score among LGBT cancer survivors.
The POMS consists of 30 adjectives that subjects rate on a five-point scale with "1" = "Not at all" and "5" = "Extremely" to describe their moods over the past week.
The total score can be calculated by adding the raw scores from tension, depression, anger, fatigue and confusion-focused items and then subtracting the vigour-focused items.
This will give a value between -24 and 177, with higher scores indicating higher psychological distress.
|
Assessed at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biological Endpoints: Cortisol
Time Frame: Assessed at 8 weeks
|
The secondary aim is to determine the preliminary effect of EXCAP-PA versus survivor-only EXCAP©® on biological endpoints associated with distress: serum cortisol among LGBT cancer survivors.
|
Assessed at 8 weeks
|
|
Biological Endpoints: Serum Amyloid A
Time Frame: Assessed at 8 weeks
|
The secondary aim is to determine the preliminary effect of EXCAP-PA versus survivor-only EXCAP©® on biological endpoints associated with distress: markers of early inflammation serum amyloid A (SAA) among LGBT cancer survivors.
|
Assessed at 8 weeks
|
|
Biological Endpoints: C-reactive Protein
Time Frame: Assessed at 8 weeks
|
The secondary aim is to determine the preliminary effect of EXCAP-PA versus survivor-only EXCAP©® on biological endpoints associated with distress: markers of C-reactive protein (CRP) among LGBT cancer survivors.
|
Assessed at 8 weeks
|
|
Mechanistic Outcomes: Support
Time Frame: Assessed at 8 weeks
|
Social support from the care partner was measured with the Dyadic Support Questionnaire (DSQ) among LGBT cancer survivors.
The DSQ is an 18-item survey based on four functions of social support (emotional, appraisal, instrumental, and informational support).
Nine items measure received social support, that is, support provided by the partner.
Items are anchored using a Likert scale ranging from 1 to 5 (from not at all to a great deal).
Items were summed to create a scale for received support ranging from 9-45, with higher scores indicating more support.
|
Assessed at 8 weeks
|
|
Mechanistic Outcomes: Adherence
Time Frame: Assessed at 8 weeks
|
We also aim to determine the preliminary effect of EXCAP-PA versus survivor-only EXCAP©® on social support from the care partners intervention adherence (actigraphy) among LGBT cancer survivors.
The actigraph features a variable epoch length which can be set between 1 to 240 seconds.
Software supplied by the manufacturer was used to determine number of minutes of moderate or higher activity during each assessment period.
|
Assessed at 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Reported Distress Among Caregivers
Time Frame: Assessed at 8 weeks
|
Self-reported psychological distress among caregivers of LGBT cancer survivors was determined using the Profile of Mood States (POMS) total score.
The POMS consists of 30 adjectives that subjects rate on a five-point scale with "1" = "Not at all" and "5" = "Extremely" to describe their moods over the past week.
The total score can be calculated by adding the raw scores from tension, depression, anger, fatigue and confusion-focused items and then subtracting the vigour-focused items.
This will give a value between -24 and 177, with higher scores indicating higher psychological distress.
|
Assessed at 8 weeks
|
|
Biological Endpoints of Distress Among Caregivers
Time Frame: Assessed at 8 weeks
|
An exploratory aim is to determine the preliminary effect of EXCAP-PA versus survivor-only EXCAP©® on biological endpoints associated with distress among caregivers of LGBT cancer survivors: serum cortisol.
|
Assessed at 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles Kamen, PhD, MPH, University of Rochester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 56965
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingRectal Neoplasms | Colon Neoplasms | Metagenome | MicrobiotaChina
-
European Association for Endoscopic SurgeryWithdrawn
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPeritoneal CarcinomatosisUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingColonic NeoplasmsChina
-
Nanjing Medical UniversityNot yet recruitingMalignant Meningioma
-
Joshua PalmerRayzeBio, Inc.RecruitingRecurrent MeningiomaUnited States
-
Chang Gung Memorial HospitalNational Science and Technology CouncilRecruiting
-
Intergroupe Francophone de Cancerologie ThoraciqueRegeneron PharmaceuticalsNot yet recruiting
-
Royal North Shore HospitalNorthern Sydney and Central Coast Area Health ServiceRecruiting
Clinical Trials on Exercise for Cancer Patients
-
University of RochesterSmartfish ASCompletedWeight Loss | Lung Cancer | Gastrointestinal Cancer | Cachexia; CancerUnited States
-
Turku University HospitalTurku AMK Master SchoolCompleted
-
Sidekick HealthUniversity of Iceland; Landspitali University Hospital; Icelandic Research CenterRecruiting
-
Muhimbili University of Health and Allied SciencesDana-Farber Cancer Institute; Erasmus Medical Center; Inkosi Albert Luthuli Central... and other collaboratorsActive, not recruitingProstate CancerNigeria, South Africa, Tanzania
-
Institut CurieCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruitingBreast Cancer | Body Weight | Nutrition Related Cancer | Lipid Cell; TumorItaly
-
University of RochesterCompletedInflammatory Bowel Diseases | Rectal Cancer | Colon Cancer | Diverticular DiseaseUnited States
-
Weill Medical College of Cornell UniversityBrown University; National Institute on Aging (NIA); Fred Hutchinson Cancer Center and other collaboratorsCompleted
-
University of ReadingUniversity of Warsaw; AZTI Spain; Maspex Poland; Natural Machines SpainCompletedCancer Patients | Taste Disorders | Food SelectionUnited Kingdom